Tepezza (teprotumumab-trbw) Coverage Criteria for Thyroid Eye Disease
Customize your policy alerts
Sign up for Bluecross Idaho Policy MP 5.01.660 alerts
Get alerted when Policy MP 5.01.660 changes without checking for updates manually.
Monitor payer policy activity
Medical-necessity coverage and authorization criteria for intravenous Tepezza in adults with moderate-to-severe thyroid eye disease associated with Graves' disease.
Clinical Activity Score reporting was removed from the policy requirements.
Statements about systemic corticosteroid therapy were clarified.
The policy statements were updated as part of the policy revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.